By Rishika Sadam March 11 (Reuters) - India's drug regulator has warned pharmaceutical companies against direct or indirect advertising of weight-loss medicines, including obesity awareness campaigns ...

India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has warned pharmaceutical companies against direct or indirect promotion of prescription weight-loss medicines, ...

The Drugs Controller General of India (DCGI) has issued strict warning against any surrogate advertisements, including awareness campaigns, for prescription-only drugs. The regulator in an advisory ...

India’s CDSCO warns pharma companies against promoting prescription weight-loss drugs like Semaglutide and Liraglutide to the public, urging ethical marketing and holistic obesity care.

The Drugs Controller General of India (DCGI) has issued strict warning against promotional activities, including “awareness campaigns," that functions as a surrogate advertisement for ...